Odyssey Therapeutics, Inc.
ODTX
$20.73
$0.010.05%
NASDAQ
| 06/30/2026 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 43.01% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 17.81% | ||||
| Operating Income | -17.81% | ||||
| Income Before Tax | -38.21% | ||||
| Income Tax Expenses | -112.70% | ||||
| Earnings from Continuing Operations | -37.96% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -37.96% | ||||
| EBIT | -17.81% | ||||
| EBITDA | -18.69% | ||||
| EPS Basic | 74.23% | ||||
| Normalized Basic EPS | 78.39% | ||||
| EPS Diluted | 74.23% | ||||
| Normalized Diluted EPS | 78.39% | ||||
| Average Basic Shares Outstanding | 435.34% | ||||
| Average Diluted Shares Outstanding | 435.34% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||